Relationship between the intracellular daunorubicin concentration expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia

Leukemia

Volumn 13, Issue 12, 1999, Pages 2023-2030

  Den Boer, M L ^a,d   Pieters, R ^a   Kazemier, K M ^a   Janka Schaub, G E ^b   Henze, G ^c   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Cell size; Childhood ALL; Drug resistance; LRP; MRP; P gp

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PREDNISOLONE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CELL LEVEL; CELL SIZE; CHILDHOOD LEUKEMIA; DRUG ACCUMULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032740589     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401576     Document Type: Article

References (56)

1. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselecled childhood acute lymphoblastic leukemia patients. Results and conclusions ot the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-313.
2. Pui CH. Childhood leukemias. New Engl J Med 1995; 332: 1618-1630.
3. Pieters R, Huismans DR, Loonen AH, Hählen K, Van der Doesvan den Berg A, Van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia, Lancet 1991; 338: 399-403.
4. Pieters R, Kaspers GJL, Van Wering ER, Huismans DR, Loonen AH, Hählen K, Veerman AJP. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
5. Skovsgaard T, Nissen NI. Membrane transport of anthracyclines. Pharmacol Ther 1982; 18: 293-311.
6. Siegfried JM, Burke TG, Tritlon TR. Cellular transport of anthracyclines by passive diffusion. Biochem Pharmacol 1985; 34: 593-598.
7. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubirin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273
8. Escriba PV, Ferrer-Montiel AV, Ferragut JA, Gonzalez-Ros JM. Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry 1990; 29: 7275-7282.
9. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
10. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996; 32A: 945-957.
11. Schuurhuis GJ, Broxterman HJ, De Lange JHM, Pinedo HM, Van Heijningen THM, Kuiper CM, Scheffer GL, Scheper RJ, Van Kalken CK, Baak JPA, Lankelma J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 1991; 64: 857-861.
12. Marquardt D, Center MS. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res 1992; 52: 3157-3163.
13. Hurwitz SJ, Terashima M, Mizunuma N, Slapak CA. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes, Blood 1997; 89: 3745-3754.
14. Scheper RJ, Broxterman HJ, Schelfer GL. Kaaijk P, Dalton WS, Van Heijningen THM, Van Kalken CK, Slovak ML, De Vries EGE, Van der Valk P, Meijer CJLM, Pinedo HM. Overexpression of a Mr 110000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-1479.
15. Scheffer GL, Wijngaard PLJ, Flens MJ. Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995; 1: 578-582.
16. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a Children's Cancer Group study. Blood 1996; 88: 309-318.
17. Tafuri A, Sommaggio A, Burba L, Albergoni MP, Petrucci MT, Mascolo MG, Testi AM, Basso G. Prognostic value of rhodamineefflux and MDR-1/P-170 expression in childhood acute leukemia, Leukemia Res 1995; 19: 927-931.
18. Pieters R, Hongo T, Loonen AH, Huismans DR, Broxterman HJ, Hählen K, Veerman AJP. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer 1992; 65: 691-697.
19. Kingreen D, Sperling C, Notter M, Schmidt C, Diddens H, Riehm H, Thiel E, Ludwig WD. Sequential analysis of P-glycoprotein expression in childhood acute lymphoblastic leukemia. Hematol Blood Transf 1992; 34: 23-28.
20. Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase π in childhood acute lymphoblastic leukaemia. Br J Cancer 1994; 70: 1144-1149.
21. Volm M, Zintl F, Edler L, Sauerbrey A. Prognostic value of protein kinase C, proto-oncogene products and resistance related proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1997; 28: 117-126.
22. Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, Bernstein ID. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia 1995; 9: 2042-2048.
23. Kaspers GJL, Veerman AJP, Pieters R, Broekema GJ, Huismans DR, Kazemier KM, Loonen AH, Rottier MMA, Van Zantwijk CH, Ḧhlen K, Van Wering ER. Mononuclear cells contaminating leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047-1052.
24. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 1995; 72: 543-549.
25. Schwartz A, Sugg H, Ritter TW, Fernandez-Repollet E. Direct determination of cell diameter, surface area, and volume with an electronic volume sensing flow cytometer. Cytometry 1983; 3: 456-458.
26. Ross DD, Thompson BW, Ordóñez JV, Joneckis CC. Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content. Cytometry 1989; 10; 185-191.
27. Stokke T, Holte H, Smeland EB, Lie SO, Steen HB. Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cells. Cancer Res 1992; 52: 5007-5012.
28. Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MMA, Flens MJ, Scheper RJ, Veerman AJP. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and ERP in childhood acute lymphoblastic leukemia. Leukemia 1997; 11: 1078-1085
29. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ, Zaman GJR. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-4563.
30. Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER, Veerman AJP. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-474.
31. Klumper E, Pieters R, Veerman AJP, Huismans DR, Loonen AH, Hählen K, Kaspers GJL, Van Wering ER, Hartmann R, Henze G. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.
32. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336.
33. Den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJP. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-2098.
34. Lilleyman JS, Stevens RF, Hann IM, Gibson BES, Britton JA, Darbyshire PJ, Oakhill A. Changes in cytomorphology of childhood lymphoblastic leukaemia at the time of disease relapse. J Clin Pathol 1995; 48: 1051-1053.
35. Tosi P, Luzi P, Miracco C, Santopietro R, Baak JPA, Bernardini C, Acquaviva A. Morphometry for the prognosis of acute lymphoblastic leukemia in childhood. Path Res Pract 1987; 182: 416-420.
36. Klumper E, Pieters R, Den Boer ML, Huismans DR, Loonen AH, Veerman AJP. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer 1995; 71: 1188-1193.
37. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Klumper E, Hählen K, De Waal FC, Van Wering ER. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 1994; 8: 24-29.
38. Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Veerman AJP. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia. Leukemia 1998; 12: 912-920.
39. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms, Eur J Cancer 1996; 32A: 1034-1038.
40. Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997; 3: 1419-1425.
41. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Hematol 1998; 103: 1083-1091.
42. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphoblastic leukaemias: biological and clinical implications. Br J Haematol 1999; 104: 328-335.
43. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, Baccarani M. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997; 96: 356-365.
44. Versantvoort CHM, Broxterman HJ, Pinedo HM, De Vries EGE, Feller N, Kuiper CM, Lankelma J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 1992; 52: 17-23.
45. Kedersha NL, Heuser JE, Chugani DC, Rome LH. Vaults, III: Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J Cell Biol 1991 ; 112: 225-235.
46. Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993; 106: 23-29.
47. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH. Vaults are up-regulated in multidrug resistant cancer cell lines. J Biol Chem 1998; 273: 8971-8974.
48. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-2469.
49. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508-1513.
50. Volm M, Stammler G, Zintl F, Koomägi R, Sauerbrey A. Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia. Anti-Cancer Drugs 1997; 8: 662-665.
51. Hart SM, Ganeshaguru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AB. Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 1997; 25: 1227-1232.
52. Izquierdo MA, Van der Zee AGJ, Vermorken JB, Van der Valk P, Beliën JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, De Vries EGE, Scheper RJ. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-1237.
53. Leith CP, Kopecky KJ, Chen IM, Eijdems J, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1, MRP1 and LRP in acute myeloid leukemia. Blood 1999; 94: 1086-1099.
54. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
55. Pallis M, Turzanski J, Harrison G, Wheatley K, Langabeer S, Burnett AK, Russell NH. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br J Haematol 1999; 104: 307-312.
56. Legrand O, Simonin G, Zittoun R, Marie JP. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 1998; 12: 1367-1374.